Medios Expands Advanced Therapies and Appoints Dr. Andreas Schmiede as VP

Berlin, August 5, 2024 – Medios AG advances its role in the Specialty Pharma sector by expanding into Advanced Therapies. The company has appointed Dr. Andreas Schmiede as Vice President, solidifying its growth strategy. Dr. Schmiede brings extensive expertise from his former position at Lonza, promising significant contributions to Medios' focus on personalized medicine.

Medios' initiative aligns with the German government's strategy to make gene- and cell-based therapies more accessible. Utilizing GMP laboratories in Europe, Medios seeks to bring high-quality personalized therapies to patients through collaborations with pharmaceutical companies and biotech firms. The effort aims to enhance patient access to innovative treatments.

CEO Matthias Gaertner emphasizes that this strategic expansion of the leadership team will drive forward innovation. CIO Christoph Prußeit notes that expanding Advanced Therapies will enable groundbreaking treatment options for patients, potentially curing diseases or correcting genetic defects. Dr. Schmiede looks forward to contributing to the future of healthcare in this dynamic industry.